Continuous erythropoietin receptor activator ameliorates diabetic kidney disease in rats

Basit Öğe Kaydı
dc.contributor.authorGünal, Mehmet Yalçın
dc.contributor.authorEren, Zehra
dc.contributor.authorBakır, Elif Arı
dc.date.accessioned2021-02-19T21:16:16Z
dc.date.available2021-02-19T21:16:16Z
dc.date.issued2020
dc.departmentALKÜ
dc.descriptiongunal, mehmet yalcin/0000-0001-7702-2441
dc.description.abstractObjective: Diabetic kidney disease (DKD) is still a significant cause of morbidity in patients with diabetes. In this study, we examined the potential effects of continuous erythropoietin receptor activator (CERA) on oxidative stress, inflammation, and the renin-angiotensin system in a rat model of DKD induced by streptozocin. Materials and Methods: A single intraperitoneal injection of streptozocin (65 mg/kg) was used in male Sprague Dawley rats to induce diabetes. The rats were randomly divided into 4 groups (n=8/group): diabetic (group D), CERA (group CR), CERA-treated diabetic group (group D+CR), and the control group (group C). The oxidative stress biomarkers, renal function parameters, messenger-ribonucleic acid expression of renin-angiotensin system parameters, and kidney histology were investigated. Results: Creatinine clearance was found to be increased and the urinary albumin-to-creatinine ratio decreased in group D+CR compared with that of group D. Serum malondialdehyde levels were significantly lower, and glutathione and glutathione peroxidase levels were significantly higher in group D+CR than those of group D. Serum interleukin-1 beta, tumor necrosis factor-alpha, and interferon-gamma levels were significantly lower; and monocyte chemoaatractant protein 1 levels were significantly higher in group D+CR than those in group D. Conclusion: CERA can protect against DKD, in part, and is related to the suppression of the renal oxidative and inflammatory response.
dc.identifier.doi10.5152/turkjnephrol.2020.3958
dc.identifier.endpage272en_US
dc.identifier.issn2667-4440
dc.identifier.issue4en_US
dc.identifier.scopusqualityQ4
dc.identifier.startpage264en_US
dc.identifier.urihttps://doi.org/10.5152/turkjnephrol.2020.3958
dc.identifier.urihttps://hdl.handle.net/20.500.12868/355
dc.identifier.volume29en_US
dc.identifier.wosWOS:000581947700003
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.institutionauthor0-belirlenecek
dc.language.isoen
dc.publisherAves
dc.relation.ispartofTurkish Journal of Nephrology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectContinuous erythropoietin receptor activator
dc.subjectdiabetic kidney disease
dc.subjectinflammation
dc.subjectoxidative stress
dc.subjectexperimental model
dc.subjectrenin-angiotensin system
dc.titleContinuous erythropoietin receptor activator ameliorates diabetic kidney disease in rats
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu